Partnership Expands One-Stop Shopping Options so That Scientists Can Focus on Novel Research
(PRWEB) May 20, 2010 -- DNA2.0, the leading gene synthesis and protein engineering company, today announced a strategic alliance with Blue Sky Biotech in order to provide customers with a seamless experience from gene synthesis to protein expression and purification. Blue Sky Biotech is a premium Contract Research Organization (CRO) for research-based drug discovery that is known for its industry-leading protein expression and purification services.
“Our alliance with DNA2.0 provides researchers with a critical advantage to help them pursue innovative medicines for unmet therapeutic needs,” said Norman Garceau, Ph.D., President and CSO of Blue Sky. “The alliance with DNA2.0 enhances our production capacity in molecular biology and provides access to DNA2.0’s patented technologies. By partnering, our clients will be able to save significant time and receive high-quality solutions.”
A cornerstone of modern biotechnology is the ability to express functional recombinant proteins in heterologous hosts. DNA2.0's rapid and efficient custom gene synthesis allows researchers to redesign entire gene sequences to maximize the likelihood of high protein expression, easy genetic manipulation, minimal promoter leakiness and convenient protein purification. Coupled with Blue Sky’s expression and purification expertise, customers can expect to benefit from major efficiencies based on shared technology enhancements as well as integrated production platforms employing DNA2.0’s optimized codon algorithms or protein expression vectors—in a wide range of host systems.
“The combined expertise of DNA2.0 and Blue Sky provides a one-stop solution for research organizations of all sizes,” said Jeremy Minshull, Ph.D., President of DNA2.0 “By focusing on providing high-quality biological reagents, we enable researchers to focus on their areas of expertise.”
While many other gene synthesis companies and CROs offshore production to laboratories in emerging economies of the world with lax IP protection, all orders through DNA2.0 and Blue Sky are produced in the USA, ensuring the greatest security for patented or confidential sequences.
About Blue Sky Biotech, Inc.
Blue Sky Biotech, Inc. is an integrated provider of custom biologicals for biomedical research and drug discovery and is organized into two divisions: BioServices and BioProducts. The BioServices division offers a wide range of custom services spanning Molecular Biology, Eukaryotic and Prokaryotic Protein Expression, Protein Purification, and Assay Development. This suite of pre-clinical services provides our clients with a convenient source of high quality custom research tools. Blue Sky also invests heavily in technology development to improve or enhance its production capabilities, including a proprietary process technology (IKM®) that significantly reduces cycle times and enhances reproducibility of protein production using baculovirus-mediated insect cell expression. The BioProducts division offers high quality biologicals and membrane protein solutions (TDA™ and SmartscreenTM Kits) designed to facilitate drug discovery. The company is a privately held corporation with over 40 staff members. It is located in Worcester, MA. For more information, please visit www.blueskybiotech.com.
Founded in 2003, DNA2.0 is the leading synthetic genomics company. It is the fastest provider of synthetic genes, based in the US with a global customer base encompassing academia, government and the pharmaceutical, chemical, agricultural and biotechnology industries. DNA2.0 explores novel applications for synthetic genes and is exploiting the synergy between highly-efficient gene synthesis process and new protein optimization technologies. The tools and applications brought to market by DNA2.0 are transforming biology into an engineering discipline. The company is privately held and is headquartered in Menlo Park, Calif. For more information, please visit www.DNA20.com.
# # #
Read the full story at http://www.prweb.com/releases/2010/05/prweb4026654.htm.
Copyright©2010 Vocus, Inc.
All rights reserved